{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.42","value":"1128"}]}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"86.19","value":"1136"}]}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.53","value":"1165"}]}],"title":"Cycle 7 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"description":"Concentration summary statistics","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG000","title":"Rucaparib 600 mg Tablets"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All patients who are treated with rucaparib with at least one pharmacokinetic (PK) measurement","reportingStatus":"POSTED","timeFrame":"Study data collection occurred over approximately 7 months.","title":"Individual Model Parameter Estimates of Rucaparib and Covariates Identification","type":"SECONDARY","unitOfMeasure":"ng/mL"}